Symposium lectures on-line

Most of the lectures of the Symposium were published on-line. You can find the video presentations at the top of each lecture abstract. We hope to complete the whole on-line program in the near feature.

Pictures of Semmelweis Symposium 2008

You can find the pictures of all the three days of Semmelweis Symposium 2008 here.

Lecture of Prof. Sándor Kovács

You can find the whole video-presentation of Prof. Sándor Kovács at "Lectures" on the following page.

Summary

More than 500 participants from 20 countries attended Semmelweis Symposium 2008. You can find a detailed summary of the event here. A summary of press echo in the Hungarian media you can find here.

Poster abstracts

You can find the poster abstracts of Semmelweis Symposium 2008 here.

Scientific Program - printable version

You can download the printable version of the Scientific Program here.

Cardiovascular pharmacogenomics course

According to the program of Semmelweis Symposium, Peter Pokreisz (Katholieke Universiteit Leuven, Belgium) will give a lecture (in Hungarian) on cGMP regulatory mechanisms in cardiology at 18:00 Wednesday, 26 November.

Abstract submission period extended

The deadline for abstract submission was extended until 18 November 2008. More detailes on the Abstract submission form.

On-line registration

Participation in the program of Semmelweis Symposium 2008 is free.
However, completion the on-line registration form is required to attend the Symposium.

Abstract submission for poster presentation

Abstracts for poster presentation are welcome to the Semmelweis Symposium. Deadline for abstract submission  is 15 November. More detailes on the Abstract Submission Form.

PhD course registration

Semmelweis Symposium 2008 was accredited by the School of Doctoral Studies of Semmelweis University. Students attending all the three days of the Symposium will get 2 PhD credits.

OFTEX registration

Semmelweis Symposium 2008 was registred to the OFTEX system. Colleagues attending all the three days of the Symposium will get 20 OFTEX credits. For detailed information look for SE-TK/2008-07/00383 at www.oftex.hu .

Final program

The final program of the Symposium has been completed. For detailes visit to the Scientific Program pages.

Current trends in Cardiology

This year cardiology is in the focus of Semmelweis Symposium. The members of the Heart Center take the opportunity to kindly invite you to this event.

Objective: Tight blood pressure (BP) control is required to reduce cardiovascular morbidity and mortality. To reach the target BP can be problematical in isolated systolic hypertension (ISH) in case of the coronary heart disease patients because of the danger of the excessive diastolic (D) BP reduction. The efficacy of indapamide in ISH was investigated in several meta-analyses, but there is no analysis which includes all of the indapamide-studies. We have searched for all relevant randomized-controlled-trials in connection with indapamide. We conducted a meta-analysis of these trials from the point of view of the ISH and the aspect of lower start BP. Design and methods: We have studied each of the randomised controlled indapamide trials (1995-2006) featured in MEDLINE database. We involved only double-blind parallel studies. Both the fixed effect model and the random effect model were used for data synthesis and results were probed with Mantel-Hanzel test as well as inverse variance test. Results: The data were combined from 9 trials that included 10108 patients. From the 9 trials 4377 patients had indapamide therapy. The average BP reduction effect of indapamide was 15.68 mmHg on systolic (S) BP and 8.85 mmHg on DBP. Data from 5 trials, included 2856 patients, was shown, that indapamide is superior to active controls in reducing SBP. The difference in SBP was 1.30 mmHg (95% CI: 0.28, 2.31). The difference in DBP was not significant (-0.16 mmHg, 95% CI: -0.80, 0,48). Pearson correlation (0.718) has close connection between start SBP and blood-pressure reduction, that showed a significant correlation (p=0.029). It can not be stated in aspect of DBP, it has low connection, the Pearson correlation = 0,202, and not significant (p=0,603). The involvement of ISH took place in 2 trials; the effect of indapamide was compared to amlodipine. There was no difference in the reduction of SBP (0.23 mmHg, 95% CI: -3.62, 4.09), but the DBP was reduced by indapamide significantly less (-3.12 mmHg, 95% CI: -5.32, -0.92). The pulse pressure reduction was: indapamide 9.3 mmHg, amlodipine 7.3 mmHg, candesartan: 7.6 mmHg, placebo: 2.7 mmHg. Compare to the placebo only the indapamide reduced significantly the pulse pressure (6.6 mmHg, 95% CI: 1,7-11.5 mmHg). Conclusions: The blood pressure reducing effect of indapamide depends on the start value of blood pressure. Indapamide is effective in the treatment of ISH in case of the elderly, especially ischemic heart disease patient.